Literature DB >> 7723938

Age-dependent accumulation of advanced glycosylation end products in human neurons.

J J Li1, M Surini, S Catsicas, E Kawashima, C Bouras.   

Abstract

Glucose can react nonenzymatically with free amino groups on proteins and form advanced glycosylation end-products (AGEPs), that have been previously isolated and characterised in aging human connective tissues. In this study, we used immunocytochemistry to examine the distribution of AGEPs in the aging human brain. Our findings show that the pyramidal neurons selectively accumulate AGEP-containing vesicles in an age-dependent manner. In addition, our results demonstrate that AGEPs accumulate in the same type of neuron that degenerates in Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7723938     DOI： 10.1016/0197-4580(95)80009-g

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  10 in total

Review 1.  From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain.

Authors:  P Riederer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

2.  Protein carbamylation is a hallmark of aging.

Authors:  Laëtitia Gorisse; Christine Pietrement; Vincent Vuiblet; Christian E H Schmelzer; Martin Köhler; Laurent Duca; Laurent Debelle; Paul Fornès; Stéphane Jaisson; Philippe Gillery
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

3.  Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis.

Authors:  J J Li; D Dickson; P R Hof; H Vlassara
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

4.  Dissociation of functional status from accrual of CML and RAGE in the aged mouse brain.

Authors:  Nopporn Thangthaeng; Nathalie Sumien; Michael J Forster
Journal:  Exp Gerontol       Date:  2008-08-26       Impact factor: 4.032

5.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.

Authors:  N Sasaki; R Fukatsu; K Tsuzuki; Y Hayashi; T Yoshida; N Fujii; T Koike; I Wakayama; R Yanagihara; R Garruto; N Amano; Z Makita
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  Involvement of Maillard reactions in Alzheimer disease.

Authors:  V Prakash Reddy; Mark E Obrenovich; Craig S Atwood; George Perry; Mark A Smith
Journal:  Neurotox Res       Date:  2002-05       Impact factor: 3.911

Review 7.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Eugenio Barone
Journal:  Biochim Biophys Acta       Date:  2014-06-17

Review 8.  Hydrogen sulfide in ageing, longevity and disease.

Authors:  Stephen E Wilkie; Gillian Borland; Roderick N Carter; Nicholas M Morton; Colin Selman
Journal:  Biochem J       Date:  2021-10-15       Impact factor: 3.857

Review 9.  BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease.

Authors:  Linda Chami; Frédéric Checler
Journal:  Mol Neurodegener       Date:  2012-10-05       Impact factor: 14.195

Review 10.  Role of methylglyoxal in Alzheimer's disease.

Authors:  Cristina Angeloni; Laura Zambonin; Silvana Hrelia
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.